8 - 10 April 2019 

Crowne Plaza Fira Center

Barcelona, Spain

China is an attractive target for pharmaceutical companies and other clinical research providers. With 58% of the country’s 1.4 billion residents living in urban areas, China promises access to more patients, in greater concentrations, than most other markets, as well as the opportunity to establish trials with treatment-naïve patients. These figures have given rise to legislation seeking to improve access to medicines and the Chinese government has recently taken unprecedented steps to improve its healthcare and regulatory system.

CHINA'S CHANGING PHARMACEUTICAL REGULATORY APPROVAL

DOWNLOAD THE FULL PAPER
Fix the following errors:
Hide